We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to ... Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. Show more
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention...
– Prophylactic administration of Gemini (Intravenous PHAD®) reduces tissue damage and improves kidney function in a rat model of bilateral ischemic reperfusion induced acute kidney injury (AKI...
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and...
-Top-line data including safety, tolerability, and biomarker activity anticipated this summer- -This Phase 1 clinical study data will support further development across multiple indications...
– Oral presentation in addition to poster presentation announced January 30, 2024 – Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, as part of a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.06 | 2.87081339713 | 2.09 | 2.31 | 2.03 | 20817 | 2.15465278 | CS |
4 | -0.45 | -17.3076923077 | 2.6 | 2.84 | 1.7801 | 43021 | 2.19915179 | CS |
12 | -0.46 | -17.6245210728 | 2.61 | 4.34 | 1.7801 | 201007 | 3.04210883 | CS |
26 | -17.35 | -88.9743589744 | 19.5 | 25.26 | 1.7801 | 275434 | 7.82940845 | CS |
52 | -28.75 | -93.0420711974 | 30.9 | 39 | 1.7801 | 210899 | 15.52407296 | CS |
156 | -8796.85 | -99.9755654052 | 8799 | 10237.5 | 1.7801 | 1271862 | 982.90521885 | CS |
260 | -8796.85 | -99.9755654052 | 8799 | 10237.5 | 1.7801 | 1271862 | 982.90521885 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions